Document is current
Any future updates will be listed below
-
Authors
Gore, Lia
Triche, Timothy J. Jr
Farrar, Jason E.
Wai, Daniel
Legendre, Christophe
Gooden, Gerald C.
Liang, Winnie S.
Carpten, John
Lee, David
Alvaro, Frank
Macy, Margaret E.
Arndt, Carola
Barnette, Philip
Cooper, Todd
Martin, Laura
Narendran, Aru
Pollard, Jessica
Meshinchi, Soheil
Boklan, Jessica
Arceci, Robert J.
Salhia, Bodour
-
Funding
Funding for this research was provided by:
National Institutes of Health (K12 CA086913-08)
Eisai
Ron Martricaria Institute of Molecular Medicine
University of Arizona
Translation Genomics Research Institute
Translational Genomics Research Institute
Johns Hopkins University
McCormick Tribune Foundation
Alex's Lemonade Stand Foundation for Childhood Cancer
Morgan Adams Foundation
St. Baldrick’s Foundation
The Lund Foundation
Najafi Fund
Arkansas Biosciences Institute.
Clark Family and Ergen Chairs in Pediatric Cancer Therapeutics at Children’s Hospital Colorado
- License Information
-
More Information
Article History
Received: 3 April 2017
Accepted: 25 September 2017
First Online: 5 October 2017
Ethics approval and consent to participate
: The study protocol was approved by each institutional review boards at every participating site and was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and all local and federal regulatory guidelines. A parent or legal guardian provided written informed consent, with patient assent as appropriate according to institutional requirements.
: Not applicable
: Mark Jones and Peter Tarassoff are former employees of Eisai Pharmaceuticals. Robert Arceci was a consultant for Pfizer. Partial support from Eisai was obtained for correlative laboratory studies (RJA, SM). There are no other potential conflicts of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
